Protalix BioTherapeutics Set to Announce 2024 Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company dedicated to advancing recombinant therapeutic proteins, has announced plans to release its financial results for the fiscal year ended December 31, 2024. The company will also provide a comprehensive business and clinical update. This important announcement is scheduled for March 17, 2025.
Conference Call to Discuss Results
Management will hold a conference call to unpack the financial results and detail recent corporate and regulatory developments. This session will present valuable insights into their strategies and future directions.
Details of the Conference Call
The conference call is set for March 17, 2025, at 8:30 a.m. Eastern Daylight Time (EDT). Participants can engage by calling:
- Toll-Free: 1-877-423-9813
- International: 1-201-689-8573
- Israeli Toll-Free: 1-809-406-247
Additionally, the conference ID to join the call will be 13752080. It's recommended that participants log in at least 15 minutes prior to the call to register and ensure their systems are ready for audio.
Webcast Access
For those unable to join the call, a webcast will be available. Interested individuals can find the webcast link on the company’s investor relations page. Additional detail will also be provided through the company's official Events Calendar.
Replay Availability
A replay of the call will be accessible for two weeks afterward, offering a chance for stakeholders to revisit the discussions and insights shared during the event.
About Protalix BioTherapeutics, Inc.
Protalix is at the forefront of biopharmaceutical advancement, focusing on the innovative production and commercialization of recombinant therapeutic proteins. Utilizing their proprietary ProCellEx system, Protalix is pioneering a new era in the development of biopharmaceuticals.
Notably, Protalix was the first company to achieve approval from the U.S. Food and Drug Administration (FDA) for a protein produced through a plant cell-based expression system. This groundbreaking achievement underscores the effectiveness and potential of their technology.
One key product in their portfolio is taliglucerase alfa, developed for treating Gaucher disease. This partnership with Pfizer Inc. allows Protalix to maintain a significant presence in the biopharmaceutical market, although they retain full rights in specific regions.
In addition to taliglucerase alfa, Protalix has recently celebrated the approval of its second product, Elfabrio®, in May 2023. This advancement further solidifies Protalix’s commitment to producing innovative therapeutic options for patients.
The company’s development pipeline is robust, featuring candidates like PRX–115, a treatment for uncontrolled gout, and PRX–119, which focuses on NETs-related diseases. This commitment to a diverse and effective pipeline demonstrates Protalix's forward-thinking approach to addressing unmet medical needs.
Investor Relations and Contact Information
For further inquiries, stakeholders can reach out to Mike Moyer, Managing Director at LifeSci Advisors, via phone at +1-617-308-4306 for any investor-related questions or details regarding the upcoming conference call.
Frequently Asked Questions
When will Protalix announce its 2024 financial results?
Protalix BioTherapeutics will announce its financial results on March 17, 2025.
How can I participate in the conference call?
You can participate by calling the provided numbers and entering the conference ID: 13752080.
Is there a way to access the call after it takes place?
Yes, a replay of the call will be available for two weeks after the event.
What is Protalix's focus within the biopharmaceutical sector?
Protalix specializes in developing and commercializing recombinant therapeutic proteins through its innovative plant cell-based production system.
Who can I contact for investor inquiries?
For investor inquiries, contact Mike Moyer at LifeSci Advisors at +1-617-308-4306.
